DELRAY
BEACH, Fla., Oct. 30,
2023 /PRNewswire/ -- PetMed Express, Inc. (NASDAQ:
PETS)("PetMeds" or "Company"), Your Trusted Pet Health Expert™,
today announced its financial results for its second quarter ended
September 30, 2023.
Quarterly Highlights
- Net sales for the quarter ended September 30, 2023, were $71.0 million, compared to $65.4 million for the second quarter in the prior
year, an increase of 9% year over year. The current quarter
includes the results from the recent acquisition of PCRx.
- PetMeds reported an increase in new customers of 25% year over
year for the quarter ended September 30,
2023, representing the fourth consecutive quarter of new
customer growth. This includes new customers from the PetCareRx
acquisition.
- Net loss for the quarter ended September
30, 2023 was $70 thousand, or
$(0.00) per diluted share. This
compares to net income of $2.6
million, or $0.13 diluted
earnings per share, for the prior year quarter ended September 30, 2022.
- Adjusted EBITDA1 of $3.2
million for the current year quarter, compared to Adjusted
EBITDA of $7.1 million, for the
quarter ended September 30, 2022, a
decrease of 55%. The decrease was due to incremental G&A in
part due to the acquisition as well as strategic investments in
PetMeds legacy third party expenses and net advertising expenses
partially offset by increased gross profit and other income.
"We are excited to see the business continue to positively
evolve into a recurring revenue business driven by our AutoShip
& Save and PetPlus programs, which represented 51% of revenue
during the quarter, up from 39% at the same time last year," said
Matt Hulett, CEO and President.
"PetMeds is focused on integrating and executing our newly acquired
partnerships and assets to provide more value to our customers,
which will also help strengthen our positioning in the pet health
space, including our core PetMeds medication customer
base."
Capital Allocation
The Board of Directors and
management have made a decision to suspend the quarterly dividend.
This will allow the Company to invest directly in the business with
a focus on organic and inorganic growth initiatives.The declaration
and payment of future dividends, if any, is discretionary and will
be subject to the determination by the Board of Directors.
Discussing the updated capital allocation strategy, Mr. Hulett
stated, "Today's announced change in capital allocation follows a
thorough and detailed analysis by our Board of Directors along with
the management team. By suspending the quarterly dividend, we have
the opportunity to invest the company's cash flow in projects and
initiatives that we believe will yield higher returns. The pet care
industry continues to grow and evolve and we believe we have
opportunities to take advantage of that growth and drive higher
returns to our shareholders."
This afternoon the Company will host a conference call to review
the quarter's financial results.
Time: 4:30 P.M. Eastern
Time, October 30, 2023
Public call dial in (877) 407-0791 (toll free) or (201)
689-8563.
Webcast stream link:
https://investors.petmeds.com/overview/default.aspx for those
who wish to stream the call via webcast.
Replay: Available until November
13, 2023, at 11:59 P.M Eastern Time.
To access the replay, call (844) 512-2921 (toll free) or (412)
317-6671 and enter passcode 13741999.
_______________________
1 Adjusted
EBITDA is a non-GAAP financial measure. See "Non-GAAP Financial
Measures" for additional information on non-GAAP financial measures
and a reconciliation to the most comparable GAAP
measures.
|
|
Founded in 1996, PetMeds is Your Trusted Pet Health
Expert™, providing prescription and non-prescription
medications, food, supplements, supplies and vet services for dogs,
cats, and horses at competitive prices direct to the consumer
through its 1-800-PetMeds toll free number and through its website
at www.petmeds.com.
This press release may contain "forward-looking" statements, as
defined in the Private Securities Litigation Reform Act of 1995 or
by the Securities and Exchange Commission, that involve a number of
risks and uncertainties, including the Company's ability to meet
the objectives included in its business plan. Important
factors that could cause results to differ materially from those
indicated by such "forward-looking" statements are set forth in the
"Risk Factors" and "Management's Discussion and Analysis of
Financial Condition and Results of Operations" section in the
Company's Annual Report on Form 10-K for the year ended
March 31, 2023. The Company's
future results may also be impacted by other risk factors listed
from time to time in its SEC filings, including, but not limited
to, the Company's Form 10-Qs and its Annual Reports on Form
10-K.
PETMED EXPRESS, INC.
AND SUBSIDIARIES
|
CONDENSED
CONSOLIDATED BALANCE SHEETS
|
(In thousands,
except for share and per share data)
|
|
|
September
30,
2023
|
|
March 31,
2023
|
|
(Unaudited)
|
|
|
ASSETS
|
|
|
|
|
|
|
|
Current
assets:
|
|
|
|
Cash and cash
equivalents
|
$
53,471
|
|
$
104,086
|
Accounts receivable,
less allowance for doubtful accounts of $44 and $35,
respectively
|
2,174
|
|
1,740
|
Inventories - finished
goods
|
18,902
|
|
19,023
|
Prepaid expenses and
other current assets
|
9,656
|
|
4,719
|
Prepaid income
taxes
|
1,457
|
|
1,883
|
Total current
assets
|
85,660
|
|
131,451
|
|
|
|
|
Noncurrent
assets:
|
|
|
|
Property and
equipment, net
|
26,968
|
|
26,178
|
Intangible and other
assets, net
|
17,181
|
|
5,860
|
Goodwill
|
22,451
|
|
–
|
Operating lease
right-of-use assets, net
|
1,826
|
|
–
|
Deferred tax assets,
net
|
5,185
|
|
628
|
Total noncurrent
assets
|
73,611
|
|
32,666
|
|
|
|
|
Total assets
|
$
159,271
|
|
$
164,117
|
|
|
|
|
LIABILITIES AND
SHAREHOLDERS' EQUITY
|
|
|
|
|
|
|
|
Current
liabilities:
|
|
|
|
Accounts
payable
|
$
25,379
|
|
$
25,208
|
Accrued expenses and
other current liabilities
|
10,986
|
|
11,289
|
Current lease
liabilities
|
757
|
|
–
|
Deferred
revenue
|
3,573
|
|
–
|
Total current
liabilities
|
40,695
|
|
36,497
|
|
|
|
|
Long-term lease
liabilities
|
1,080
|
|
–
|
Other long-term
liabilities
|
3,825
|
|
3,825
|
|
|
|
|
Total
liabilities
|
45,600
|
|
40,322
|
|
|
|
|
Commitments and
contingencies
|
|
|
|
|
|
|
|
Shareholders'
equity:
|
|
|
|
Preferred stock,
$.001 par value, 5,000,000 shares authorized; 2,500 convertible
shares issued and outstanding with a liquidation preference
of $4 per share
|
9
|
|
9
|
Common stock, $.001
par value, 40,000,000 shares authorized; 21,147,006 and
21,084,302 shares issued and outstanding, respectively
|
21
|
|
21
|
Additional paid-in
capital
|
21,765
|
|
18,277
|
Retained
earnings
|
91,876
|
|
105,488
|
|
|
|
|
Total shareholders'
equity
|
113,671
|
|
123,795
|
|
|
|
|
Total liabilities and
shareholders' equity
|
$
159,271
|
|
$
164,117
|
PETMED EXPRESS, INC.
AND SUBSIDIARIES
|
CONDENSED
CONSOLIDATED STATEMENTS OF INCOME
|
(In thousands,
except for share and per share amounts) (Unaudited)
|
|
|
Three Months
Ended
September 30,
|
|
Six Months
Ended
September 30,
|
|
2023
|
|
2022
|
|
2023
|
|
2022
|
|
|
|
|
|
|
|
|
Sales
|
$
70,999
|
|
$
65,394
|
|
$
149,243
|
|
$
135,581
|
Cost of
sales
|
50,937
|
|
46,943
|
|
106,655
|
|
97,187
|
|
|
|
|
|
|
|
|
Gross profit
|
20,062
|
|
18,451
|
|
42,588
|
|
38,394
|
|
|
|
|
|
|
|
|
Operating
expenses:
|
|
|
|
|
|
|
|
General and
administrative
|
13,278
|
|
10,753
|
|
28,989
|
|
20,104
|
Advertising
|
5,512
|
|
3,879
|
|
12,777
|
|
10,228
|
Depreciation and
amortization
|
1,713
|
|
858
|
|
3,391
|
|
1,611
|
Total operating
expenses
|
20,503
|
|
15,490
|
|
45,157
|
|
31,943
|
|
|
|
|
|
|
|
|
(Loss) income from
operations
|
(441)
|
|
2,961
|
|
(2,569)
|
|
6,451
|
|
|
|
|
|
|
|
|
Other
income:
|
|
|
|
|
|
|
|
Interest income,
net
|
570
|
|
388
|
|
1,190
|
|
505
|
Other, net
|
254
|
|
261
|
|
760
|
|
459
|
Total other
income
|
824
|
|
649
|
|
1,950
|
|
964
|
|
|
|
|
|
|
|
|
Income (loss) before
provision for income taxes
|
383
|
|
3,610
|
|
(619)
|
|
7,415
|
|
|
|
|
|
|
|
|
Provision for income
taxes
|
453
|
|
1,031
|
|
338
|
|
2,061
|
|
|
|
|
|
|
|
|
Net (loss)
income
|
$
(70)
|
|
$
2,579
|
|
$
(957)
|
|
$
5,354
|
|
|
|
|
|
|
|
|
Net (loss) income per
common share:
|
|
|
|
|
|
|
|
Basic
|
$
(0.00)
|
|
$
0.13
|
|
$
(0.05)
|
|
$
0.26
|
Diluted
|
$
(0.00)
|
|
$
0.13
|
|
$
(0.05)
|
|
$
0.26
|
|
|
|
|
|
|
|
|
Weighted average number
of common shares outstanding:
|
|
|
|
|
|
|
|
Basic
|
20,382,979
|
|
20,261,114
|
|
20,357,752
|
|
20,234,904
|
Diluted
|
20,382,979
|
|
20,343,980
|
|
20,357,752
|
|
20,317,522
|
|
|
|
|
|
|
|
|
Cash dividends declared
per common share
|
$
0.30
|
|
$
0.30
|
|
$
0.60
|
|
$
0.60
|
PETMED EXPRESS, INC.
AND SUBSIDIARIES
|
CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS
|
(In thousands)
(Unaudited)
|
|
|
Six Months
Ended
September 30,
|
|
2023
|
|
2022
|
Cash flows from
operating activities:
|
|
|
|
Net (loss)
income
|
$
(957)
|
|
$
5,354
|
Adjustments to
reconcile net (loss) income to net cash provided by operating
activities:
|
|
|
|
Depreciation and
amortization
|
3,391
|
|
1,611
|
Share based
compensation
|
3,489
|
|
3,217
|
Deferred income
taxes
|
(81)
|
|
(389)
|
Bad debt
expense
|
36
|
|
66
|
(Increase) decrease in
operating assets and increase (decrease) in operating
liabilities:
|
|
|
|
Accounts
receivable
|
(345)
|
|
257
|
Inventories - finished
goods
|
3,237
|
|
(1,567)
|
Prepaid income
taxes
|
426
|
|
86
|
Prepaid expenses and
other current assets
|
(3,516)
|
|
(597)
|
Operating lease
right-of-use assets, net
|
394
|
|
–
|
Accounts
payable
|
(5,542)
|
|
(3,520)
|
Accrued expenses and
other current liabilities
|
(943)
|
|
590
|
Lease
liabilities
|
(383)
|
|
–
|
Deferred
revenue
|
579
|
|
–
|
Income taxes
payable
|
–
|
|
–
|
Net cash (used in)
provided by operating activities
|
$
(215)
|
|
$
5,108
|
|
|
|
|
Cash flows from
investing activities:
|
|
|
|
Purchase of minority
interest investment in Vetster
|
–
|
|
(5,000)
|
Acquisition of
PetCareRx, net of cash acquired
|
(35,859)
|
|
–
|
Purchases of property
and equipment
|
(2,137)
|
|
(2,336)
|
Net cash used in
investing activities
|
$
(37,996)
|
|
$
(7,336)
|
|
|
|
|
Cash flows from
financing activities:
|
|
|
|
Dividends
paid
|
(12,404)
|
|
(12,306)
|
Net cash used in
financing activities
|
$
(12,404)
|
|
$
(12,306)
|
|
|
|
|
Net decrease in cash
and cash equivalents
|
(50,615)
|
|
(14,534)
|
Cash and cash
equivalents, at beginning of period
|
104,086
|
|
111,080
|
|
|
|
|
Cash and cash
equivalents, at end of period
|
$
53,471
|
|
$
96,546
|
|
|
|
|
Supplemental disclosure
of cash flow information:
|
|
|
|
|
|
|
|
Cash paid for income
taxes
|
$
–
|
|
$
2,560
|
|
|
|
|
Dividends payable in
accrued expenses
|
$
1,513
|
|
$
856
|
|
Non-GAAP Financial Measures
To provide investors and the market with additional information
regarding our financial results, we have disclosed (see below)
adjusted EBITDA, a non-GAAP financial measure that we calculate as
net income excluding share-based compensation expense; depreciation
and amortization; income tax provision; interest income (expense);
and other non-operational expenses. We have provided
reconciliations below of adjusted EBITDA to net income, the most
directly comparable GAAP financial measures.
We have included adjusted EBITDA, herein, because it is a key
measure used by our management and Board of Directors to evaluate
our operating performance, generate future operating plans, and
make strategic decisions regarding the allocation of capital. In
particular, the exclusion of certain expenses in calculating
adjusted EBITDA facilitates operating performance comparability
across reporting periods by removing the effect of non-cash
expenses and other expenses. Accordingly, we believe that adjusted
EBITDA provides useful information to investors and others in
understanding and evaluating our operating results in the same
manner as our management and Board of Directors.
We believe it is useful to exclude non-cash charges, such as
share-based compensation expense, depreciation and amortization
from our adjusted EBITDA because the amount of such expenses in any
specific period may not directly correlate to the underlying
performance of our business operations. We believe it is useful to
exclude income tax provision and interest income (expense), as
neither are components of our core business operations. We also
believe that it is useful to exclude other expenses, including the
investment banking fee related to the Vetster partnership,
acquisition costs related to PetCareRx, employee severance and
estimated state sales tax accrual as these items are not indicative
of our ongoing operations. Adjusted EBITDA has limitations as a
financial measure, and these non-GAAP measures should not be
considered in isolation or as a substitute for analysis of our
results as reported under GAAP. Some of these limitations are:
- Although depreciation and amortization are non-cash charges,
the assets being depreciated and amortized may have to be replaced
in the future and adjusted EBITDA does not reflect capital
expenditure requirements for such replacements or for new capital
expenditures;
- Adjusted EBITDA does not reflect share-based compensation.
Share-based compensation has been, and will continue to be for the
foreseeable future, a material recurring expense in our business
and an important part of our compensation strategy;
- Adjusted EBITDA does not reflect interest income (expense),
net; or changes in, or cash requirements for, our working
capital;
- Adjusted EBITDA does not reflect transaction related costs and
other items which are either not representative of our underlying
operations or are incremental costs that result from an actual or
planned transaction and include litigation matters, integration
consulting fees, internal salaries and wages (to the extent the
individuals are assigned full-time to integration and
transformation activities) and certain costs related to integrating
and converging IT systems;
- Adjusted EBITDA does not reflect certain non-operating expenses
including the employee severance which reduces cash available to
us;
- Adjusted EBITDA does not reflect certain expenses including the
estimated state sales tax accrual which reduces cash available to
us.
- Other companies, including companies in our industry, may
calculate adjusted EBITDA differently, which reduces the measures
usefulness as comparative measures.
Because of these and other limitations, adjusted EBITDA should
only be considered as supplemental to, and alongside with other
GAAP based financial performance measures, including various cash
flow metrics, net income, net margin, and our other GAAP
results.
The following table presents a reconciliation of net income, the
most directly comparable GAAP measure to adjusted EBITDA for each
of the periods indicated:
Reconciliation of
Non-GAAP Measures
|
PetMed Express,
Inc.
|
(Unaudited)
|
|
|
Three Months
Ended
|
|
|
|
|
($ in thousands,
except percentages)
|
September
30,
2023
|
|
September
30,
2022
|
|
$
Change
|
|
%
Change
|
|
|
|
|
|
|
|
|
Consolidated
Reconciliation of GAAP Net (Loss) Income to Adjusted
EBITDA:
|
|
|
|
|
|
|
|
|
Net (loss)
income
|
$
(70)
|
|
$
2,579
|
|
$
(2,649)
|
|
(103) %
|
|
|
|
|
|
|
|
|
Add
(subtract):
|
|
|
|
|
|
|
|
Share-based
Compensation
|
$
1,729
|
|
$
1,682
|
|
$
47
|
|
3 %
|
Income
Taxes
|
$
453
|
|
$
1,031
|
|
$
(578)
|
|
(56) %
|
Depreciation and
Amortization
|
$
1,713
|
|
$
858
|
|
$
855
|
|
100 %
|
Interest Income,
net
|
$
(570)
|
|
$
(388)
|
|
$
(182)
|
|
47 %
|
Acquisition/Partnership Transactions and Other
Items
|
$
168
|
|
$
–
|
|
$
168
|
|
n/m
|
Employee
Severance
|
$
15
|
|
$
364
|
|
$
(349)
|
|
(96) %
|
State Sales Tax
Accrual
|
$
(268)
|
|
$
925
|
|
$
(1,193)
|
|
(129) %
|
Adjusted
EBITDA
|
$
3,170
|
|
$
7,051
|
|
$
(3,881)
|
|
(55) %
|
|
Six Months
Ended
|
|
|
|
|
($ in thousands,
except percentages)
|
September
30,
2023
|
|
September
30,
2022
|
|
$
Change
|
|
%
Change
|
|
|
|
|
|
|
|
|
Consolidated
Reconciliation of GAAP Net (Loss) Income to Adjusted
EBITDA:
|
|
|
|
|
|
|
|
|
Net (loss)
income
|
$
(957)
|
|
$
5,354
|
|
$
(6,311)
|
|
(118) %
|
|
|
|
|
|
|
|
|
Add
(subtract):
|
|
|
|
|
|
|
|
Share-based
Compensation
|
$
3,489
|
|
$
3,218
|
|
$
271
|
|
8 %
|
Income
Taxes
|
$
338
|
|
$
2,061
|
|
$
(1,723)
|
|
(84) %
|
Depreciation and
Amortization
|
$
3,391
|
|
$
1,611
|
|
$
1,780
|
|
110 %
|
Interest Income,
net
|
$
(1,190)
|
|
$
(505)
|
|
$
(685)
|
|
136 %
|
Acquisition/Partnership Transactions and Other
Items
|
$
1,294
|
|
$
355
|
|
$
939
|
|
265 %
|
Employee
Severance
|
$
408
|
|
$
364
|
|
$
44
|
|
12 %
|
State Sales Tax
Accrual
|
$
(268)
|
|
$
925
|
|
$
(1,193)
|
|
n/m
|
Adjusted
EBITDA
|
$
6,505
|
|
$
13,383
|
|
$
(6,878)
|
|
(51) %
|
View original
content:https://www.prnewswire.com/news-releases/petmeds-announces-its-second-quarter-financial-results-301971860.html
SOURCE PetMed Express Inc